ストックスクリーナーアプリを入手
10.78
2.71%
-0.30
アフターアワーズ：
10.78
前日終値:
$11.08
開ける：
$11.03
24時間の取引高:
2.36M
Relative Volume:
0.86
時価総額：
$2.37B
収益：
$52.04M
当期純損益:
$-290.50M
株価収益率:
-7.4054
EPS:
-1.4557
ネットキャッシュフロー:
$-240.94M
1週間 パフォーマンス:
+1.22%
1か月 パフォーマンス:
+26.75%
6か月 パフォーマンス:
+20.38%
1年 パフォーマンス:
-12.36%
1日の値動き範囲:
$10.61
$11.05
1週間の範囲:
$10.30
$11.74
52週間の値動き範囲:
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
名前
Ocular Therapeutix Inc
セクター
電話
781-357-4000
住所
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
10.78 | 2.44B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-15 | 開始されました | Chardan Capital Markets | Buy |
| 2025-04-08 | 開始されました | William Blair | Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-03-11 | 開始されました | Needham | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-20 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-02-09 | 開始されました | BofA Securities | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-08-10 | 再開されました | Berenberg | Buy |
| 2021-08-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-11-13 | 繰り返されました | Raymond James | Strong Buy |
| 2020-08-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-03 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-05-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-21 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 開始されました | Raymond James | Strong Buy |
| 2018-09-07 | 開始されました | Piper Jaffray | Overweight |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-07-12 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-06-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-08-11 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-02-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Ocular Therapeutix Inc (OCUL) 最新ニュース
META_TITLE_QUOTE - Yahoo Finance
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance
Ocular (OCUL) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Latest Session; Market Reaction: The Stock Ends Down 5.46% in the Available RecordPost-Announcement Reaction - vinanet.vn
Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the DayAdjusted Earnings Analysis - vinanet.vn
Ocular Therapeutix (OCUL) Institutional Ownership 2026 - MarketBeat
Clear Street Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Why Is Ocular Therapeutix Stock Gaining Monday? - Sahm
OCUL Looks 134.8% Overvalued on GF Value™ - GuruFocus
OCUL Stock Climbs As FDA Clears Path For AXPAXLI NDA - StocksToTrade
OCUL Stock Climbs As FDA Path And Cash Runway De‑Risk Story - timothysykes.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap UpShould You Buy? - MarketBeat
Why is Ocular Therapeutix stock rallying today? By Investing.com - Investing.com Canada
OCUL Looks 141.9% Overvalued on GF Value™ - GuruFocus
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles By Investing.com - Investing.com South Africa
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles - Investing.com
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate - Stocktwits
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
(OCUL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued? - Sahm
OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210 - TradingKey
Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research - MarketBeat
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option - Stock Titan
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL - MarketBeat
The debate of durability in nAMD - Endpoints News
Ocular Therapeutix, Inc. $OCUL Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat
Ocular Therapeutix (OCUL) Holds Steady Near $9.24 as Key Resistance Looms at $9.70Institutional Buy Signals - vinanet.vn
Does Ocular Therapeutix (OCUL) Pairing Flat Revenue With a New Shelf Point to a Shifting Funding Strategy? - Sahm
Ocular Therapeutix (NASDAQ:OCUL) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Ocular Therapeutix Options for New Hires Carry $8.40 Price - Stock Titan
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS) - The Globe and Mail
Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results - simplywall.st
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says - marketscreener.com
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Exploring a 222% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Ocular Therapeutix Reports Second Quarter Revenue, Provides Business Highlights - VisionMonday.com
Sticking With This Ocular Therapeutix Price Target as Key Treatment Moves Forward - TheStreet Pro
Ocular Therapeutix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ocular Therapeutix Inc earnings beat by $0.03, revenue topped estimates - Investing.com
Ocular Therapeutix reports Q2 2026: $13.5M revenue, $78.8M net loss, $598.6M cash - TradingView
Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026 - Yahoo Finance
Ocular Therapeutix 2026: Revenue $13.48M, EPS ($0.35) — 10-Q Summary - TradingView
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q2 Revenue $13.5M, vs. FactSet Est of $13.2M - marketscreener.com
OCULAR THERAPEUTIX, INC Quarterly Earnings Report - Stock Titan
Ocular Therapeutix's Q2 Net Loss Widens, Revenue Flat - finance.yahoo.com
Ocular Therapeutix Reports Q2 2026 Results, Confirms Q4 2026 AXPAXLI NDA Submission Plan for Wet AMD - Quiver Quantitative
Defilade Capital Management L.P. Purchases 805,982 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix Inc (OCUL) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):